Payment overview · 2025
General Payments
$406.69
26 reported records · 9 companies
Healthcare provider profile · identity verified
Michael J Hayes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARION, OH · NPI 1174587943
Verified facts
What the public records show
CMS Open Payments records show Michael J Hayes, M.D. received $406.69 in general payments during 2025 across 26 reported records.
GlaxoSmithKline, LLC. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.17 | 33.7% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.12 | 19.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.63 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.88 | 8.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.70 | 8.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.44 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.86 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.77 | 3.9% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $14.12 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.69 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $121.37 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.68 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 681 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 579 | 156 |
| Lisinopril | Lisinopril | 558 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 118 |
| Metformin Hcl | Metformin Hcl | 431 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 114 |
| Omeprazole | Omeprazole | 329 | 84 |
| Carvedilol | Carvedilol | 293 | 69 |
| Alprazolam | Alprazolam | 281 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 263 | 103 |
| Furosemide | Furosemide | 253 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 62 |
| Gabapentin | Gabapentin | 227 | 51 |
| Glimepiride | Glimepiride | 217 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 57 |
| Tramadol Hcl | Tramadol Hcl | 211 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 54 |
| Trazodone Hcl | Trazodone Hcl | 195 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 51 |
| Eliquis | Apixaban | 181 | 44 |
| Methylprednisolone | Methylprednisolone | 174 | 120 |
| Ropinirole Hcl | Ropinirole Hcl | 173 | 43 |
| Simvastatin | Simvastatin | 150 | 43 |
| Potassium Chloride | Potassium Chloride | 143 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 45 |
| Amoxicillin | Amoxicillin | 121 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 58 |
| Synthroid | Levothyroxine Sodium | 118 | 29 |
| Azithromycin | Azithromycin | 115 | 92 |
| Famotidine | Famotidine | 108 | 38 |
| Farxiga | Dapagliflozin Propanediol | 107 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 34 |
| Allopurinol | Allopurinol | 102 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 24 |
| Meloxicam | Meloxicam | 100 | 32 |
| Ozempic | Semaglutide | 97 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 23 |
| Donepezil Hcl | Donepezil Hcl | 57 | 11 |
| Warfarin Sodium | Warfarin Sodium | 56 | 16 |
| Finasteride | Finasteride | 55 | 14 |
| Ramipril | Ramipril | 54 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Montelukast Sodium | Montelukast Sodium | 53 | 19 |
| Pitavastatin Calcium | Pitavastatin Calcium | 51 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 32 |
| Sertraline Hcl | Sertraline Hcl | 48 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 39 |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Cefuroxime | Cefuroxime Axetil | 45 | 31 |
| Nifedipine Er | Nifedipine | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Mirtazapine | Mirtazapine | 43 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Spironolactone | Spironolactone | 36 | 13 |
| Valsartan | Valsartan | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 20 |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Clarithromycin | Clarithromycin | 21 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clarithromycin Er | Clarithromycin | 12 | 12 |
| Diazepam | Diazepam | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.69 · 26 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error